Strides Pharma Science Limited — Investor Meet, 21-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Strides Pharma Science reported robust FY26 results: EBITDA at INR925 Cr (+15% YoY) with margins expanding to 19%, and operational PAT at INR518 Cr (+50% YoY). Ex-U.S. markets drove growth (+19% 3-year CAGR), now contributing nearly 50% of Q4 revenue, marking a structural shift. U.S. business, affected by flu season, targets $375-$400 million by FY28, backed by controlled substances and new R&D in nasal sprays and other complex generics from H2 FY27. The Sandoz acquisition strengthens the African branded business. Management aims for >20% EBITDA margins, highlighting disciplined profitability and a stronger balance sheet.